You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Biological Activity Assay and Bioanalytical Test Method Development for a Silk-Derived Protein (SDP) Eye Drop Product

    SBC: SILK TECHNOLOGIES, LTD.            Topic: NonDoD

    The company has developed a silk-derived protein (SDP) for use as a novel ophthalmic formulation excipient that will help to treat the ocular injuries and dry eye pathology that affects over 40 million Americans annually and hundreds of millions of people worldwide. The SDP excipient is designed to enhance tear formulation comfort, longevity, and overall ocular health. This proposal builds on the ...

    SBIR Phase II 2019 Department of DefenseDefense Health Agency
  2. THIS SBIR PHASE I CONTRACT IS FOR A WEARABLE ALCOHOL BIOSENSOR THAT QUANTIFIES BAC IN REAL TIME.

    SBC: DeLeon, Augustina S            Topic: NIAAA

    Technology validation study of a wearable NIR spectrometer to quantify BAC in real time

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Electrochemical aptasensor for Anti-Tuberculosis antibiotic quantification

    SBC: GUILD ASSOCIATES INC            Topic: NIAID

    Specific AimsIn Phase I of this SBIRwe will complete three specific aimssynthesize stable combination adjuvant formulations that are compatible with an HVLP antigenidentify the combination adjuvant properties that augment the safe and durable immunity to Handdemonstrate the superior protective benefit of the new combination adjuvant over existing adjuvant solutions for pandemic influenza vaccinesI ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. TOPIC 386: NOVEL ORALLY BIOAVAILABLE PDE-CATENIN INHIBITOR CONCENTRATES IN LUNG FOR CANCER CHEMOPREVENTION

    SBC: ADT Pharmaceuticals, LLC            Topic: NCI

    This application is based on ADT Pharmaceuticalsdiscoveries thatthe cGMP degrading phosphodiesterase isozymephosphodiesteraseAPDEis overexpressed during early stages of tumorigenesisgenetic knockdown of PDEresults in selective apoptosis of tumor cells by activating cGMP PKG signalingandsmall molecule inhibitors of PDEinduce apoptosis by PKG phosphorylation of oncogeniccateninthereby suppressing Tc ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. TOPIC 396- IMAGING FOR CANCER IMMUNOTHERAPIES-MOONSHOT

    SBC: COLUMBUS NANOWORKS, INC.            Topic: NCI

    In vivo imaging of cells labeled with fluorescent nanodiamondsFNDsis a new way of monitoring immune cells during cancer immunotherapyFNDs are non toxicinfinitely photostable nanomaterials that are easily conjugated with antibodiesand emit fluorescence in the near infrared spectral regionIn this Phase I SBIRwe will use a murine melanoma model and outline a plan to use FNDs for imaging immunosupress ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC #366- PHASE II SBIR CONTRACT- CLONOGENIC HIGH- THROUGHPUT ASSAY FOR SCREENING RADIATION MODULATION

    SBC: SUVICA INC            Topic: NCI

    Clonogenic assays measure the ability of single cells to proliferate and form a colonyThis process approximates closely the regrowth and recurrence of tumors after treatment with radiation or chemotherapyproviding an assay to screen for drugs that block this processYetclonogenic assays are labor intensive and too cumbersome for high throughout screeningHTSof compound librariesHere we propose to de ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. TOPIC 389- INTELLIGENT SOFTWARE FOR RADIATION THERAPY PLANNING

    SBC: RADIASOFT LLC            Topic: NCI

    Besides surgeryradiotherapy is the most effective treatment modality for localized prostate cancerThe success of radiotherapy stems from the exploit of a therapeutic window in tumor response and normal tissue tolerance which maximizes the chance of sterilizing the tumor while sparing the surrounding normal tissue from severe damageThis requires an accurate and individualized radiation dose distrib ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Strong protections, tracking, diversion detection, and deactivation of opioid medications in the hospital and related caregiving settings.

    SBC: Curazel LLC            Topic: NIDA

    Under the Small Business Innovation Research ProgramSBIRPhase I programTopicthe Contractor will develop a comprehensive approach to allow hospitals gain control of their opioid medicationsThe Contractor approach is totrack opioids from the pharmacy to the patienttrack the amount given to the patientand for opioid waste to track it back to the pharmacybetter administer opioids to patients that offe ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Improving Spatiotemporal Precision in Noninvasive Electrical Neuromodulation

    SBC: Brain Electrophysiology Laboratory Company, LLC            Topic: 101

    This application describes the commercialization of the Geodesic Transcranial Electrical Neuromodulation (GTEN) technology to achieve noninvasive neuromodulation with improved spatiotemporal precision. The GTEN system enables both EEG source analysis and configurable electrical neuromodulation with the 256 electrodes of the Geodesic Sensor Net. Now in beta release to selected research customers, t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. STING Inhibitor Discovery for Rare and Common Autoimmune Diseases

    SBC: DISCOVERYBIOMED, INC.            Topic: NIAID

    Principal Investigators for Small BusinessDiscoveryBioMedIncDBMand Nitor TherapeuticsIncNitorProject Summary Abstract The over arching commercial goal for this Nitor TherapeuticsIncNitorand DiscoveryBioMedIncDBMcollaboration is to discover and validate Stimulator of Interferon Genes orSTINGinhibitor ligands in a novel high throughput screeningHTSand validation based Critical Path of bioassaysAberr ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government